UA76638C2 - Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon - Google Patents
Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon Download PDFInfo
- Publication number
- UA76638C2 UA76638C2 UA20041210911A UA20041210911A UA76638C2 UA 76638 C2 UA76638 C2 UA 76638C2 UA 20041210911 A UA20041210911 A UA 20041210911A UA 20041210911 A UA20041210911 A UA 20041210911A UA 76638 C2 UA76638 C2 UA 76638C2
- Authority
- UA
- Ukraine
- Prior art keywords
- interferon
- antibodies
- dilutions
- gamma
- homeopathic
- Prior art date
Links
- 102000014150 Interferons Human genes 0.000 title claims abstract description 19
- 108010050904 Interferons Proteins 0.000 title claims abstract description 19
- 229940079322 interferon Drugs 0.000 title claims abstract description 18
- 230000001632 homeopathic effect Effects 0.000 title claims abstract description 13
- 238000000034 method Methods 0.000 title claims abstract description 10
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 7
- 230000001575 pathological effect Effects 0.000 title claims abstract description 6
- 239000003814 drug Substances 0.000 title abstract description 18
- 229940079593 drug Drugs 0.000 title abstract description 14
- 230000001064 anti-interferon Effects 0.000 title abstract description 6
- 238000010790 dilution Methods 0.000 claims abstract description 19
- 239000012895 dilution Substances 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 238000005516 engineering process Methods 0.000 claims abstract description 7
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 4
- 230000007246 mechanism Effects 0.000 claims abstract description 4
- 102000008070 Interferon-gamma Human genes 0.000 claims description 13
- 108010074328 Interferon-gamma Proteins 0.000 claims description 13
- 229940044627 gamma-interferon Drugs 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 10
- 102000003996 Interferon-beta Human genes 0.000 claims description 4
- 108090000467 Interferon-beta Proteins 0.000 claims description 4
- 229940126601 medicinal product Drugs 0.000 claims description 4
- 238000013207 serial dilution Methods 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 description 10
- 230000000242 pagocytic effect Effects 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 210000003708 urethra Anatomy 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 230000028996 humoral immune response Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000295644 Staphylococcaceae Species 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 230000000686 immunotropic effect Effects 0.000 description 2
- 230000036515 potency Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037569 Purulent discharge Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 238000002555 auscultation Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000000544 hyperemic effect Effects 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000001937 intercostal nerve Anatomy 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000011867 re-evaluation Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Alternative & Traditional Medicine (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/RU2002/000369 WO2005000350A1 (en) | 2002-08-02 | 2002-08-02 | Medication and method for treating pathological syndrome |
Publications (1)
Publication Number | Publication Date |
---|---|
UA76638C2 true UA76638C2 (en) | 2006-08-15 |
Family
ID=33550540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UA20041210911A UA76638C2 (en) | 2002-08-02 | 2002-02-08 | Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon |
Country Status (7)
Country | Link |
---|---|
US (3) | US7572441B2 (ru) |
EP (1) | EP1547613A4 (ru) |
AU (1) | AU2002325435A1 (ru) |
EA (1) | EA008106B1 (ru) |
IL (1) | IL166656A0 (ru) |
UA (1) | UA76638C2 (ru) |
WO (1) | WO2005000350A1 (ru) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2181297C2 (ru) * | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
UA76638C2 (en) | 2002-08-02 | 2006-08-15 | Oleh Illich Epshtein | Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon |
UA76639C2 (ru) * | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Гомеопатическое лекарственное средство и способ лечения эректильных дисфункций |
UA76641C2 (ru) * | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Гомеопатическое лекарственное средство и способ лечения заболеваний предстательной железы |
RU2253478C1 (ru) * | 2003-10-01 | 2005-06-10 | Эпштейн Олег Ильич | Средство для потенцирования лечебных эффектов - усиления действия лекарственного вещества |
RU2309732C1 (ru) * | 2006-03-13 | 2007-11-10 | Олег Ильич Эпштейн | Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата |
EA200802440A1 (ru) * | 2006-06-06 | 2009-06-30 | Олег Ильич ЭПШТЕЙН | Лекарственное средство для лечения ожирения, сахарного диабета и заболеваний с нарушением толерантности к глюкозе |
RU2332236C1 (ru) * | 2007-02-02 | 2008-08-27 | Олег Ильич Эпштейн | Лекарственное средство для лечения гриппа у птиц |
DE602008004898D1 (de) | 2008-06-27 | 2011-03-24 | Theranor Sprl | Pharmazeutische Zusammensetzungen von Antikörpern von Viruserkrankungen |
CN102770758B (zh) | 2009-12-22 | 2015-12-16 | Atonarp株式会社 | 检测化学物质的装置及方法 |
MY165267A (en) | 2010-07-15 | 2018-03-15 | Oleg Lliich Epshtein | Combination pharmaceutical composition and methods of treating genitourinary system disorders |
PE20130397A1 (es) | 2010-07-15 | 2013-04-10 | Oleg Iliich Epshtein | Composicion farmaceutica combinada y metodos para el tratamiento de las enfermedades o condiciones funcionales del tracto gastrointestinal |
SG187034A1 (en) | 2010-07-15 | 2013-02-28 | Oleg Iliich Epshtein | A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system |
US9308275B2 (en) | 2010-07-15 | 2016-04-12 | Oleg Iliich Epshtein | Method of increasing the effect of an activated-potentiated form of an antibody |
JP2013532182A (ja) | 2010-07-15 | 2013-08-15 | イリイチ・エプシテイン オレグ | 組み合わせ医薬組成物及び神経変性疾患に関連する疾患又は状態を治療する方法 |
EP2593477A2 (en) | 2010-07-15 | 2013-05-22 | Oleg Iliich Epshtein | Pharmaceutical compositions and methods of treatment |
KR20130102542A (ko) * | 2010-07-21 | 2013-09-17 | 올레그 일리치 엡쉬테인 | 현기증, 동요병 및 증식형-혈관 이긴장증 치료용 제약학적 복합 조성물 및 치료 방법들 |
ES2425315R1 (es) | 2010-07-21 | 2014-09-08 | Oleg Iliich Epshtein | Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria |
EP2596020A2 (en) | 2010-07-21 | 2013-05-29 | Oleg Iliich Epshtein | Method of treatment of organic diseases of nervous system, psychoorganic syndrome and encephalopathy |
MY160979A (en) | 2010-07-21 | 2017-03-31 | Oleg Llich Epshtein | A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders |
EA029399B1 (ru) | 2010-07-21 | 2018-03-30 | Олег Ильич ЭПШТЕЙН | Комбинированная фармацевтическая композиция для лечения болезни альцгеймера и способ лечения болезни альцгеймера |
GB2496343B (en) | 2010-07-21 | 2017-11-01 | Iliich Epshtein Oleg | A method of treating attention deficit hyperactivity disorder |
RU2517084C2 (ru) | 2010-08-06 | 2014-05-27 | Олег Ильич Эпштейн | Способ и средство для ингибирования продукции или усиления элиминации белка р24 |
BR112013002296A2 (pt) | 2010-08-06 | 2018-01-30 | Lliich Epshtein Oleg | composição farmacêutica e respectivo uso e método para tratar doença infecciosa |
RU2535034C2 (ru) | 2010-08-06 | 2014-12-10 | Олег Ильич Эпштейн | Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида |
RU2010133049A (ru) | 2010-08-06 | 2012-02-20 | Олег Ильич Эпштейн (RU) | Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида |
US20130171161A1 (en) * | 2010-12-23 | 2013-07-04 | Oleg Iliich Epshtein | Method and composition for the treatment of diseases caused by or associated with hiv |
RU2013111961A (ru) | 2013-03-18 | 2014-09-27 | Олег Ильич Эпштейн | Способ определения выраженности модифицирующей активности, ассоциированной с носителем |
RU2013111962A (ru) | 2013-03-18 | 2014-09-27 | Олег Ильич Эпштейн | Способ определения выраженности модифицирующей активности, ассоциированной с носителем |
RU2603623C2 (ru) | 2014-06-06 | 2016-11-27 | Олег Ильич Эпштейн | Ветеринарная композиция и способ улучшения жизнеспособности животных, стимуляции прироста живой массы млекопитающих и птиц, повышения эффективности иммунизации, профилактики и/или лечения инфекционных заболеваний (варианты) |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4963367A (en) * | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
SU1331508A1 (ru) | 1985-08-14 | 1987-08-23 | Киевский Кабельный Завод "Укркабель" | Устройство дл пневматического массажа урогенитальной сферы человека |
US4987127A (en) * | 1989-01-31 | 1991-01-22 | Dal Sirany | Method of treating a virus outbreak |
SU1730144A1 (ru) | 1989-02-24 | 1992-04-30 | Научный Центр По Разработке И Внедрению Современных Методов Молекулярной Диагностики | Способ подавлени репродукции вирусов |
GB8905400D0 (en) | 1989-03-09 | 1989-04-19 | Jonker Margreet | Medicaments |
US5698195A (en) * | 1991-03-18 | 1997-12-16 | New York University Medical Center | Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies |
RU2007989C1 (ru) | 1991-11-12 | 1994-02-28 | Акционерное общество "Трейдис" | Способ габович подбора гомеопатических препаратов и их разовой дозы |
DK140992D0 (da) | 1992-11-24 | 1992-11-24 | Ole Buchardt | Fremgangsmaade til frembringelse af antistoffer mod haptener og andre b-celle-antigener, antistoffer opnaaet ved fremgangsmaaden og anvendelse af disse antistoffer til fremstilling af vacciner, isaer til veterinaermedicinsk brug |
WO1994022846A1 (en) | 1993-03-30 | 1994-10-13 | Pfizer Inc. | Compounds enhancing antitumor activity of other cytotoxic agents |
RU2033784C1 (ru) | 1993-05-28 | 1995-04-30 | Индивидуальное частное предприятие "Диалог" | Устройство для репродуцирования гомеопатических и изопатических препаратов |
IT1261849B (it) * | 1993-09-02 | 1996-06-03 | Avantgarde Spa | Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici. |
EP0652014A1 (en) | 1993-11-10 | 1995-05-10 | National Institute Of Immunology | Treatment of prostatic hypertrophy |
US5629286A (en) | 1994-03-31 | 1997-05-13 | Brewitt; Barbara | Homeopathic dilutions of growth factors |
IL110035A0 (en) | 1994-06-16 | 1994-10-07 | Tapuach Natural Technologies 1 | Homeopathic formulations |
RU2137483C1 (ru) | 1995-08-02 | 1999-09-20 | Божедомов Владимир Александрович | Способ лечения урогенитальной хламидийной, уреаплазменной и микоплазменной инфекции |
EA000885B1 (ru) | 1996-02-12 | 2000-06-26 | Олег Ильич ЭПШТЕЙН | Лекарственное средство и способ медикаментозного воздействия на организм |
IL118096A0 (en) * | 1996-05-01 | 1996-09-12 | Yeda Res & Dev | Antibodies against interferon alpha/beta receptor |
RU2114605C1 (ru) | 1996-09-30 | 1998-07-10 | Олег Ильич Эпштейн | Защитная добавка для косметических средств |
RU2114646C1 (ru) | 1996-09-30 | 1998-07-10 | Олег Ильич Эпштейн | Способ повышения защитных свойств организма при воздействии внешних физических факторов |
RU2099052C1 (ru) | 1996-12-26 | 1997-12-20 | Тамара Михайловна Воробьева | Лекарственное средство для восстановления психофизиологического гомеостаза, нарушенного вследствие употребления алкоголя |
RU2103999C1 (ru) | 1997-01-31 | 1998-02-10 | Олег Ильич Эпштейн | Способ лечения алкоголизма |
RU2104032C1 (ru) | 1997-03-11 | 1998-02-10 | Общество с ограниченной ответственностью "Снежный барс" | Способ усиления лечебного эффекта лекарственных средств |
RU2122858C1 (ru) | 1997-12-29 | 1998-12-10 | Яковлева Людмила Борисовна | Гомеопатическое лекарственное средство седативного действия "вернисон" |
JP4372347B2 (ja) * | 1998-03-11 | 2009-11-25 | あすか製薬株式会社 | 発泡性腸溶製剤 |
RU2187334C2 (ru) * | 1998-05-22 | 2002-08-20 | Эпштейн Олег Ильич | Способ коррекции нарушенного иммунного гомеостаза и лекарственное средство |
RU2144370C1 (ru) | 1999-01-06 | 2000-01-20 | Титиева Наталья Михайловна | Гомеопатическое лекарственное средство для лечения гипертрофии предстательной железы |
RU2161955C1 (ru) | 1999-07-16 | 2001-01-20 | Эпштейн Олег Ильич | Способ изменения физико-химических или физико-химических и биологических свойств вещества |
RU2181297C2 (ru) | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
RU2177795C1 (ru) | 2001-02-15 | 2002-01-10 | Эпштей Олег Ильич | Гомеопатическое лекарственное средство для лечения и профилактики аденовирусных инфекций у детей |
US7087726B2 (en) * | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
RU2197266C1 (ru) | 2001-06-01 | 2003-01-27 | Эпштейн Олег Ильич | Лекарственное средство и способ лечения эрозивных и воспалительных заболеваний желудочно-кишечного тракта |
WO2003037372A1 (fr) | 2001-10-31 | 2003-05-08 | Oleg Iliich Epshtein | Procede de retablissement de processus physiologiques perturbes et medicament |
RU2001134982A (ru) | 2001-12-26 | 2004-02-20 | Олег Ильич Эпштейн | Способ коррекции иммунного ответа и лекарственное средство |
RU2201255C1 (ru) | 2001-12-26 | 2003-03-27 | Эпштейн Олег Ильич | Лекарственное средство и способ регуляции сосудистого тонуса |
RU2205026C1 (ru) | 2002-03-15 | 2003-05-27 | Эпштейн Олег Ильич | Лекарственное средство и способ лечения патологического синдрома, обусловленного нарушением кроветворения |
UA76641C2 (ru) | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Гомеопатическое лекарственное средство и способ лечения заболеваний предстательной железы |
UA76640C2 (ru) * | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Способ коррекции патологических иммунных реакций и гомеопатическое лекарственное средство |
UA76638C2 (en) * | 2002-08-02 | 2006-08-15 | Oleh Illich Epshtein | Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon |
UA76639C2 (ru) * | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Гомеопатическое лекарственное средство и способ лечения эректильных дисфункций |
RU2253478C1 (ru) * | 2003-10-01 | 2005-06-10 | Эпштейн Олег Ильич | Средство для потенцирования лечебных эффектов - усиления действия лекарственного вещества |
RU2281784C1 (ru) | 2005-04-20 | 2006-08-20 | Научно-исследовательский институт детских инфекций (НИИДИ) | Способ предупреждения клещевого энцефалита у детей |
RU2309732C1 (ru) | 2006-03-13 | 2007-11-10 | Олег Ильич Эпштейн | Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата |
RU2332236C1 (ru) | 2007-02-02 | 2008-08-27 | Олег Ильич Эпштейн | Лекарственное средство для лечения гриппа у птиц |
RU2326694C1 (ru) | 2007-02-02 | 2008-06-20 | Олег Ильич Эпштейн | Лекарственное средство для лечения инфекционных заболеваний домашних животных, в том числе вирусной этиологии |
JP2013532182A (ja) | 2010-07-15 | 2013-08-15 | イリイチ・エプシテイン オレグ | 組み合わせ医薬組成物及び神経変性疾患に関連する疾患又は状態を治療する方法 |
MY165267A (en) | 2010-07-15 | 2018-03-15 | Oleg Lliich Epshtein | Combination pharmaceutical composition and methods of treating genitourinary system disorders |
PE20130397A1 (es) | 2010-07-15 | 2013-04-10 | Oleg Iliich Epshtein | Composicion farmaceutica combinada y metodos para el tratamiento de las enfermedades o condiciones funcionales del tracto gastrointestinal |
MY160979A (en) | 2010-07-21 | 2017-03-31 | Oleg Llich Epshtein | A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders |
KR20130102542A (ko) | 2010-07-21 | 2013-09-17 | 올레그 일리치 엡쉬테인 | 현기증, 동요병 및 증식형-혈관 이긴장증 치료용 제약학적 복합 조성물 및 치료 방법들 |
BR112013002296A2 (pt) * | 2010-08-06 | 2018-01-30 | Lliich Epshtein Oleg | composição farmacêutica e respectivo uso e método para tratar doença infecciosa |
-
2002
- 2002-02-08 UA UA20041210911A patent/UA76638C2/uk unknown
- 2002-08-02 WO PCT/RU2002/000369 patent/WO2005000350A1/ru not_active Application Discontinuation
- 2002-08-02 US US10/522,652 patent/US7572441B2/en not_active Expired - Lifetime
- 2002-08-02 EP EP02759007A patent/EP1547613A4/en active Pending
- 2002-08-02 AU AU2002325435A patent/AU2002325435A1/en not_active Abandoned
- 2002-08-02 EA EA200500098A patent/EA008106B1/ru not_active IP Right Cessation
-
2005
- 2005-02-02 IL IL16665605A patent/IL166656A0/xx unknown
-
2009
- 2009-06-30 US US12/495,104 patent/US8066992B2/en not_active Expired - Fee Related
-
2011
- 2011-10-20 US US13/277,646 patent/US8815245B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US7572441B2 (en) | 2009-08-11 |
EP1547613A4 (en) | 2006-02-01 |
US8066992B2 (en) | 2011-11-29 |
EA008106B1 (ru) | 2007-04-27 |
EP1547613A1 (en) | 2005-06-29 |
AU2002325435A8 (en) | 2005-01-13 |
EA200500098A1 (ru) | 2005-08-25 |
US8815245B2 (en) | 2014-08-26 |
IL166656A0 (en) | 2006-01-15 |
US20090285781A1 (en) | 2009-11-19 |
WO2005000350A1 (en) | 2005-01-06 |
US20060024307A1 (en) | 2006-02-02 |
US20120045445A1 (en) | 2012-02-23 |
AU2002325435A1 (en) | 2005-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA76638C2 (en) | Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon | |
US6294171B2 (en) | Methods for treating disease states comprising administration of low levels of antibodies | |
RU2192888C1 (ru) | Лекарственное средство и способ лечения патологического синдрома | |
UA76641C2 (ru) | Гомеопатическое лекарственное средство и способ лечения заболеваний предстательной железы | |
EA008104B1 (ru) | Лекарственное средство и способ лечения эректильных дисфункций | |
RU2187334C2 (ru) | Способ коррекции нарушенного иммунного гомеостаза и лекарственное средство | |
EA008605B1 (ru) | Лекарственное средство для коррекции патологических иммунных реакций | |
WO2003055518A1 (fr) | Procede de traitement d'etats immuno-pathologiques et medicament correspondant | |
RU2192882C1 (ru) | Лекарственное средство и способ лечения патологического синдрома, обусловленного нарушением кроветворения | |
De Maeyer et al. | Delayed hypersensitivity to Newcastle disease virus in high and low interferon-producing mice. | |
RU2191601C1 (ru) | Лекарственное средство и способ лечения эректильных дисфункций | |
RU2413507C2 (ru) | Способ лечения сиалоаденита | |
RU2500426C2 (ru) | Способ лечения инфекционных заболеваний, вызванных вирусом гриппа с типом поверхностного антигена h5n1, и лекарственное средство для лечения инфекционных заболеваний, вызванных вирусом гриппа с типом поверхностного антигена h5n1 | |
RU2205026C1 (ru) | Лекарственное средство и способ лечения патологического синдрома, обусловленного нарушением кроветворения | |
RU2005136271A (ru) | Способ диагностики и лечения неврологических повреждений у детей раннего возраста | |
US11491197B2 (en) | Multiple viral antigen COVID vaccine and therapeutic | |
WO2003037372A1 (fr) | Procede de retablissement de processus physiologiques perturbes et medicament | |
RU2209083C1 (ru) | Лекарственное средство и способ лечения кашля | |
RU2625744C1 (ru) | Способ профилактики обострения бронхиальной астмы и хронической обструктивной болезни легких | |
WO2004012765A1 (fr) | Preparation medicinale et procede de traitement d'un syndrome pathologique determine par une perturbation de l'hematopoiese | |
RU2206338C1 (ru) | Способ лечения синдрома кашля | |
AU2002248189B2 (en) | Methods for treating disease states comprising administration of low levels of antibodies | |
RU2200579C1 (ru) | Способ профилактики и лечения респираторных болезней телят | |
RU2097037C1 (ru) | Способ лечения аллергодерматозов у детей | |
RU2180238C1 (ru) | Биологический препарат для профилактики и лечения желудочно-кишечных и респираторных болезней телят |